Liraglutide 3.0mg Effective for Weight Regain After Gastric Bypass Surgery

For individuals struggling with severe obesity, Roux-en-Y gastric bypass (RYGB) surgery is a highly effective intervention, leading to significant initial weight loss. However, a substantial number of patients experience weight regain over time, diminishing the long-term benefits of the surgery and posing a significant clinical challenge. There is a critical need for safe and effective pharmacological strategies to manage weight regain in post-RYGB patients.

The study demonstrated that Liraglutide 3.0mg significantly reduced body weight in patients with post-RYGB weight regain. Participants treated with Liraglutide achieved a mean weight loss of 8.5% from baseline, which was significantly greater than the placebo group's 1.2% weight loss (p<0.001). The most important finding was that 70% of patients in the Liraglutide group achieved at least 5% total body weight loss, compared to only 25% in the placebo group (p<0.001). Furthermore, 35% of Liraglutide-treated patients achieved >10% weight loss, while only 5% of placebo patients reached this threshold (p<0.001). Adverse events were consistent with the known profile of Liraglutide, primarily gastrointestinal, with nausea reported by 35% in the active group versus 10% in the placebo group, and vomiting by 18% versus 4%.